# A MolEcularly Guided Anti-Cancer Drug Off-Label Trial

> **NCT04185831** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Uppsala University Hospital** · enrollment: 167 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Everolimus
- **DRUG:** Cobimetinib
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT04185831
- **Lead sponsor:** Uppsala University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-20
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-10
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04185831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04185831, "A MolEcularly Guided Anti-Cancer Drug Off-Label Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04185831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*